

Syrma SGS Technology

Estimate change	↑
TP change	↔
Rating change	↔

Bloomberg	SYRMA IN
Equity Shares (m)	192
M.Cap.(INRb)/(USDb)	146.7 / 1.6
52-Week Range (INR)	910 / 355
1, 6, 12 Rel. Per (%)	8/-2/33
12M Avg Val (INR M)	1078

Financials & Valuations (INR b)

Y/E Mar	FY26E	FY27E	FY28E
Sales	49.4	65.2	83.3
EBITDA	5.5	7.2	9.2
Adj. PAT	3.4	4.7	6.1
EBITDA Margin (%)	11.1	11.1	11.1
Cons. Adj. EPS (INR)	17.6	24.6	31.6
EPS Gr. (%)	81.8	40.4	28.3
BV/Sh. (INR)	171.6	196.6	229.2

Ratios

Net D:E	-0.2	-0.2	-0.2
RoE (%)	14.0	14.5	16.0
RoCE (%)	13.6	14.9	17.1

Valuations

P/E (x)	43	31	24
EV/EBITDA (x)	25	19	15

Shareholding Pattern (%)

As on	Dec-25	Sep-25	Dec-24
Promoter	42.7	43.0	46.6
DII	15.9	16.4	7.5
FII	6.6	7.1	8.6
Others	34.8	33.5	37.4

Note: FII includes depository receipts

CMP: INR755 TP: INR1,000 (+32%) Buy

Robust performance across all segments

Operating performance beats our estimates

- Syрма SGS Technology (SYRMA) continued its strong operating performance, with EBITDA up ~2x YoY in 3QFY26. EBITDA margin expanded 350bp YoY due to a favorable business mix and operating leverage. Revenue grew 45%, largely led by a strong jump in IT/Railways revenue (up 65%), followed by Healthcare/Industrial/Auto/Consumer (up 47%/45%/44%/43% YoY).
- The order book continued to improve to INR64b as of Dec'25 (up ~21%/10% YoY/QoQ). Moreover, with a strong 9MFY26, management has revised its guidance upwards with more than INR5b of EBITDA in FY26, with revenue guidance of ~INR1.6b in 4QFY26. Further, the company has guided for a 30% growth in revenue/EBITDA for FY27 (with EBITDA margins of 10%).
- Factoring in the strong operating performance, we raise our EPS estimate by 19% for FY26, while largely maintaining our FY27/FY28 estimate. We reiterate our **BUY** rating on the stock with a **TP of INR1,000 (32x FY28E EPS)**.

Business mix and operating leverage underpin margin expansion

- Consolidated revenue grew 45.4% YoY to INR12.6b (est. INR12b), led by growth across all segments. IT and Railways grew the highest (up 65%), followed by Healthcare/Industrial/Auto/Consumer (up 47%/45%/44%/43% YoY).
- EBITDA margins expanded 350bp YoY to 12.6% (est. 9.6%), led by a decrease in the share of employees and other expenses. EBITDA grew ~2x YoY to INR1.6b (est. INR1.1b). Adj. PAT grew ~2x YoY to INR1.1b (est. INR713m). The company had a labor code impact of INR33.8m (reported in exceptional items).
- The order book stood at INR64b in Dec'25 vs INR58b as of Sep'25. The order book mix comprised Auto/Consumer/Industrial at 31%/25%/27%, with the balance attributed to Healthcare, IT, and Railway as of Dec'25.
- Gross debt stood at INR5.3b as of Dec'25 vs. INR6.1b as of Mar'25. Net working capital days stood at 76 days as of Dec'25, with management targeting to reduce it by another 3-5 days over the next 2-3 quarters.

Research Analyst: Sumant Kumar (Sumant.Kumar@MotilalOswal.com) | **Meet Jain** (Meet.Jain@MotilalOswal.com)

Research Analyst: Nirvik Saini (Nirvik.Saini@MotilalOswal.com) | **Yash Darak** (Yash.Darak@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

Highlights from the management commentary

- **Export:** The company reported strong export growth of 65%/45% in 3QFY26/9MFY26, with export revenue rising to INR3.4b/INR8.4b. Exports accounted for 25% of the business mix in 9MFY26 (vs 21% in 9MFY25). During 3QFY26, exports of INR1b/INR1.8b were reported in the healthcare/industrial segment. The company has further guided for export revenue of INR11b in FY27.
- **Elcome:** SYRMA completed the acquisition of a 60% stake in Dec'25 for INR2.4b, with financials consolidated for the relevant period of Dec'25 (around 15–16 days). On a standalone basis, Elcome is expected to generate revenue of INR 2.8–3.0b in FY26 (not fully consolidated), with margins in the range of 20–25%. The company expects this revenue to grow 10–15% in FY27.
- **PCB manufacturing:** A capital infusion and equity allotment of ~INR450m in the ratio of 75% (Syrma SGS)/25% (Shinhyup, Korea) has been completed during the quarter. The company expects to spend a capex of INR3.6–4b for the first phase (to be completed by Dec'26). This would entail a capacity of 720,000 square meters of multi-layer line and 480,000 square meters of single-layer PCBs.

Valuation and view


- SYRMA continued its earnings momentum, driven by a favorable shift in the business mix and operating leverage in 3QFY26. We expect this trend to continue through 4Q/FY27, led by strong growth in higher-margin segments, such as automotive and industrial.
- We believe that the company's long-term trajectory will continue to remain strong, backed by: 1) its focus on low-volume, high-margin business; 2) an increase in exports; 3) increasing share of revenue in the industrial and automotive segments; 4) a foray into bare PCB manufacturing through its JV; and 5) inorganic expansion into new verticals, such as defense and solar invertors.
- We estimate a revenue/EBITDA/adj. PAT CAGR of 30%/45%/52% over FY25-28, driven by strong revenue growth and margin expansion. We reiterate our BUY rating on the stock with a **TP of INR1,000 (premised on 32x FY28E EPS)**.

Consolidated - Quarterly Earning

Consolidated - Quarterly Earning									(INR m)			
Y/E March	FY25				FY26E				FY25	FY26E	FY26E	Var
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE				
Gross Sales	11,599	8,327	8,692	9,244	9,440	11,459	12,642	15,899	37,862	49,439	12,000	5
YoY Change (%)	92.9	17.0	23.0	-18.5	-18.6	37.6	45.4	72.0	20.1	30.6	38.1	
Total Expenditure	11,153	7,618	7,901	8,169	8,574	10,307	11,048	14,180	34,841	44,107	10,853	
EBITDA	446	710	791	1,075	866	1,152	1,594	1,719	3,021	5,332	1,147	39
Margins (%)	3.8	8.5	9.1	11.6	9.2	10.1	12.6	10.8	8.0	10.8	9.6	
Depreciation	174	167	202	208	206	218	203	225	751	852	220	
Interest	130	136	154	156	149	126	77	75	577	427	95	
Other Income	153	100	223	223	160	87	103	100	699	451	200	
PBT before EO expense	295	507	657	934	672	895	1,417	1,519	2,392	4,503	1,032	
Extra-Ord expense	0	0	21	0	0	0	34	0	21	34	0	
PBT	295	507	635	934	672	895	1,383	1,519	2,371	4,469	1,032	
Tax	91	110	105	219	172	232	280	365	526	1,049	260	
Rate (%)	31.0	21.8	16.6	23.5	25.7	25.9	20.3	24.0	22.2	23.5	25.2	
MI & Profit/Loss of Asso. Cos.	10	34	42	60	2	23	75	84	147	184	59	
Reported PAT	193	362	488	654	497	641	1,028	1,071	1,698	3,237	713	
Adj PAT	193	362	509	654	497	641	1,055	1,071	1,719	3,263	713	48
YoY Change (%)	-32.3	22.0	228.2	87.3	157.8	76.8	107.1	63.6	58.2	89.8	40.0	
Margins (%)	1.7	4.4	5.9	7.1	5.3	5.6	8.3	6.7	4.5	6.6	5.9	


Key exhibits

Exhibit 1: Consolidated revenue trend




Source: Company, MOFSL

Exhibit 2: Consolidated EBITDA trend




Source: Company, MOFSL

Exhibit 3: Consolidated Adj. PAT trend




Source: Company, MOFSL

Exhibit 4: End-user industry mix




Source: Company, MOFSL

Exhibit 5: Closing order book trend



Source: MOFSL, Company

Exhibit 6: Revenue growth YoY across end-user verticals



Source: MOFSL, Company



Highlights from the management commentary

Operating performance

- The company reported robust growth across all parameters.
- It reported a 65%/45% growth in exports, reaching INR3350m/INR8370m for 3QFY26/9MFY26. The export business mix stood at 25% for 9MFY26, driven mainly by industrial and healthcare. The company recorded exports of INR1b/INR1.8b in the healthcare/industrial segments.
- MEdtech exports are majorly to US, while RFID exports are largely directed toward the EU.
- For 9MFY26, Industrial/Healthcare exports included 90%/55% to Europe/US.
- Annualized amount for PLI is ~INR300-320m.
- ODM contribution for the quarter stands at 16%.
- Margins have expanded due to a higher export mix; increased contribution from ODM, industrial, and healthcare; and a lower share of low-margin business.
- CFO for 9MFY26 stood positive for the company.
- Gross debt as of Dec'25 stood at INR5.3b, with cash and cash equivalents at INR9.3b. Net cash as of Dec'25 stood at INR4b.
- FTA with EU is expected to be positive for SYRMA. The company has a plant in Germany.

Outlook and guidance

- SYRMA revised its EBITDA guidance upwards to more than INR5b for FY26, with revenue guidance of more than INR1.6b in 4QFY26.
- Revenue and EBITDA growth guidance for FY27 is 30%.
- The company expects to deliver a blended EBITDA margin of 10% in FY27.
- It expects to reach INR11b in exports by FY27.

Acquisition of Elcome Integrated Systems Pvt Ltd

- SYRMA consummated the acquisition of 60% stake in Dec'25 for INR2.4b.
- The financials for relevant period have been consolidated as of Dec'25 (15-16 days).
- Elcome is a completely domestic business. Elcome is solely expected to report a revenue of INR2.8-3b for FY26 (not to be consolidated fully) with margins of 20-25%. The company expects a 10-15% growth on this revenue in FY27.

PCBs manufacturing

- SYRMA has partnered with Shinhyup Electronics Co., Ltd., South Korea, to establish capabilities in multi-layer and flexible PCBs.
- A capital infusion and equity allotment of ~INR450m in the ratio of 75% (Syrma SGS) / 25% (Shinhyup, Korea) has been completed during the quarter.
- The company has initiated site development activities, with civil infrastructure construction currently in process.
- PLI and state incentive approvals have been obtained from the central/state governments.
- The company has planned a capex of INR3.6-4b for the first phase (to be completed by Dec'26). This would entail a capacity of 720,000 square meters of multi-layer line and 480,000 square meters of single-layer PCBs.

- INR15b of total capex includes CCL, HDI, and flex. The company is yet to receive approvals from the government, as it will be initiating those projects in FY27-28. It is planning to spend the entire INR15b by FY30.
- PCB related capex is expected to be raised 50%/50% through debt/equity. Of the overall 50% equity, 25% will be contributed by the collaborator. A capex of INR3.5-4b by FY27 will make the company eligible for a subsidy from Andhra Pradesh.

Order book

- As of Dec'25, the orderbook stood at INR64b.
- The Auto/Consumer/Industrial mix of the order book stands at 31%/25%/27%, with the balance attributed to Healthcare, IT, and railway.

Industrial

- The industrial segment is driven by exports and other applications, excluding smart meters, which contributed ~INR500m, with others applications like power supply, exports contributing the rest.
- Smart meters may contribute ~INR2b this year, with growth expectations of 25-30% in FY27.

Others

- The transaction closure regarding Elemaster JVA is in process.
- The transaction closure conditions for the acquisition of Ksolare by the JV (with Premier Energies) are currently being progressed.
- With respect to the merger, the company has already concluded the transaction.
- The company has been able to renegotiate interest with bankers; closing debt was not available for the full quarter, resulting in lower interest.
- Tax rate for the fourth quarter is expected to be ~23-24%, while for FY27, it is expected to be ~26%.

Valuation and view

- SYRMA continued its earnings momentum, driven by a favorable shift in the business mix and operating leverage in 3QFY26. We expect this trend to continue through 4Q/FY27, led by strong growth in higher-margin segments, such as automotive and industrial.
- We believe that the company's long-term trajectory will continue to remain strong, backed by: 1) its focus on low-volume, high-margin business; 2) an increase in exports; 3) increasing share of revenue in the industrial and automotive segments; 4) a foray into bare PCB manufacturing through its JV; and 5) inorganic expansion into new verticals, such as defense and solar invertors.
- We estimate a revenue/EBITDA/adj. PAT CAGR of 30%/45%/52% over FY25-28, driven by strong revenue growth and margin expansion. We reiterate our BUY rating on the stock with a **TP of INR1,000 (premised on 32x FY28E EPS)**.

Exhibit 7: Changes to our estimates

Earnings change (INR m)	Old			New			Change		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY27E
Revenue	48,151	65,546	83,663	49,439	65,244	83,277	3%	0%	0%
EBITDA	4,685	6,893	8,926	5,491	7,242	9,244	17%	5%	4%
Adj. PAT	2,839	4,501	5,872	3,376	4,739	6,081	19%	5%	4%
EPS	15	23	31	18	25	32	19%	5%	4%

Financials and valuations

Consolidated - Income Statement

(INR m)

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Total Income from Operations	8,858	12,667	20,484	31,538	37,862	49,439	67,222	85,808
Change (%)	2.8	43.0	61.7	54.0	20.1	30.6	36.0	27.6
RM Cost	6,276	9,408	15,405	25,069	29,258	37,030	50,887	64,871
Employees Cost	781	823	1,060	1,426	1,887	2,145	2,689	3,432
Other Expenses	786	1,148	2,142	3,059	3,696	4,933	6,386	8,066
Total Expenditure	7,842	11,380	18,606	29,554	34,841	44,107	59,962	76,369
% of Sales	88.5	89.8	90.8	93.7	92.0	89.2	89.2	89.0
EBITDA	1,016	1,287	1,878	1,984	3,021	5,332	7,260	9,439
Margin (%)	11.5	10.2	9.2	6.3	8.0	10.8	10.8	11.0
Depreciation	228	249	312	515	751	852	1,136	1,342
EBIT	789	1,038	1,566	1,469	2,270	4,480	6,124	8,097
Int. and Finance Charges	97	108	216	378	577	427	205	132
Other Income	177	178	437	587	699	451	941	1,201
PBT bef. EO Exp.	869	1,108	1,787	1,678	2,392	4,503	6,860	9,166
EO Items	0	0	0	14	21	34	0	0
PBT after EO Exp.	869	1,108	1,787	1,664	2,371	4,469	6,860	9,166
Total Tax	213	343	556	421	526	1,049	1,727	2,307
Tax Rate (%)	24.5	31.0	31.1	25.3	22.2	23.5	25.2	25.2
Minority Interest	25	42	38	170	147	184	360	606
Reported PAT	630	722	1,193	1,073	1,698	3,237	4,773	6,253
Adjusted PAT	630	722	1,193	1,087	1,719	3,262	4,773	6,253
Change (%)	-28.7	14.5	65.2	-8.9	58.2	89.8	46.3	31.0
Margin (%)	7.1	5.7	5.8	3.4	4.5	6.6	7.1	7.3

Consolidated - Balance Sheet

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Equity Share Capital	46	1,376	1,768	1,774	1,780	1,923	1,923	1,923
Preference Capital	0	0	0	0	0	0	0	0
Total Reserves	5,946	4,344	13,635	14,352	15,719	28,524	33,009	38,974
Net Worth	5,992	5,721	15,403	16,126	17,500	30,447	34,932	40,897
Minority Interest	6	108	26	644	749	933	1,293	1,898
Total Loans	1,029	2,183	3,468	5,763	6,112	2,912	1,912	1,612
Deferred Tax Liabilities	62	124	138	176	139	139	139	139
Capital Employed	7,089	8,136	19,035	22,710	24,499	34,431	38,276	44,546
Gross Block	2,264	3,233	4,821	8,134	9,077	10,189	13,987	15,186
Less: Accum. Deprn.	405	635	947	1,462	2,213	3,065	4,201	5,543
Net Fixed Assets	1,858	2,597	3,874	6,672	6,864	7,124	9,786	9,643
Goodwill on Consolidation	1,059	1,182	1,182	3,221	3,221	3,221	3,221	3,221
Capital WIP	0	408	253	168	609	747	999	600
Total Investments	1,316	410	8,500	419	594	594	594	594
Current Investments	0	0	780	355	514	514	514	514
Curr. Assets, Loans&Adv.	5,365	6,945	11,603	26,414	30,758	45,658	54,830	70,257
Inventory	1,789	2,913	5,874	10,043	8,219	10,836	14,365	18,337
Account Receivables	2,084	2,722	4,032	9,301	14,775	19,234	26,152	33,383
Cash and Bank Balance	729	369	544	856	2,958	9,655	6,919	9,098
Loans and Advances	763	940	1,151	6,215	4,807	5,933	7,394	9,439
Curr. Liability & Prov.	2,509	3,407	6,377	14,185	17,548	22,913	31,155	39,769
Account Payables	1,848	2,405	4,881	12,232	15,744	20,558	27,952	35,681
Other Current Liabilities	554	857	1,362	1,778	1,597	2,085	2,836	3,620
Provisions	108	145	134	174	207	270	367	468
Net Current Assets	2,856	3,538	5,226	12,230	13,211	22,745	23,676	30,488
Misc Expenditure	0	0	0	0	0	0	0	0
Appl. of Funds	7,089	8,136	19,035	22,710	24,499	34,431	38,276	44,546

Financials and valuations

Ratios

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Basic (INR)								
EPS	4.6	5.2	6.7	6.1	9.7	17.6	24.6	31.6
Cash EPS	6.2	7.1	8.5	9.0	13.9	23.8	33.0	41.7
BV/Share	43.5	41.6	87.1	90.9	98.3	171.6	196.6	229.2
DPS	0.0	0.0	0.0	1.5	1.5	1.5	1.5	1.5
Payout (%)	0.0	0.0	0.0	24.8	15.7	8.6	6.1	4.7
Valuation (x)								
P/E	164.9	144.0	111.9	123.3	78.2	43.0	30.6	23.9
Cash P/E	121.2	107.0	88.7	83.7	54.5	31.7	22.9	18.1
P/BV	17.3	18.2	8.7	8.3	7.7	4.4	3.8	3.3
EV/Sales	11.8	8.4	6.6	4.4	3.6	2.8	2.2	1.7
EV/EBITDA	102.6	82.3	72.3	70.2	45.6	25.3	19.4	15.0
Dividend Yield (%)	0.0	0.0	0.0	0.2	0.2	0.2	0.2	0.2
FCF per share	1.3	-7.5	-12.1	-25.4	0.2	1.7	-8.8	8.8
Return Ratios (%)								
RoE	12.3	12.3	11.3	6.9	10.2	14.0	14.5	16.0
RoCE	11.7	11.2	10.3	7.5	10.2	13.6	14.9	17.1
RoIC	12.6	11.9	12.9	7.1	8.5	16.2	17.3	18.8
Working Capital Ratios								
Fixed Asset Turnover (x)	3.9	3.9	4.2	3.9	4.2	4.9	4.7	5.5
Asset Turnover (x)	1.2	1.6	1.1	1.4	1.5	1.4	1.7	1.9
Inventory (Days)	74	84	105	116	79	80	78	78
Debtor (Days)	86	78	72	108	142	142	142	142
Creditor (Days)	76	69	87	142	152	152	152	152
Leverage Ratio (x)								
Current Ratio	2.1	2.0	1.8	1.9	1.8	2.0	1.8	1.8
Interest Cover Ratio	8.1	9.6	7.3	3.9	3.9	10.8	29.8	59.8
Net Debt/Equity	0.1	0.3	0.1	0.3	0.2	-0.2	-0.2	-0.2

Consolidated - Cash Flow Statement

(INR m)

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
OP/(Loss) before Tax	869	1,108	1,787	1,664	2,371	4,503	6,860	9,166
Depreciation	228	249	312	515	751	852	1,136	1,342
Interest & Finance Charges	52	54	-222	378	585	-23	-736	-1,069
Direct Taxes Paid	-220	-289	-556	-540	-607	-1,049	-1,727	-2,307
(Inc)/Dec in WC	-499	-1,212	-2,140	-2,804	-934	-2,836	-3,667	-4,633
CF from Operations	430	-90	-818	-786	2,165	1,447	1,866	2,499
Others	-58	-36	115	-350	-400	0	0	0
CF from Operating incl EO	371	-126	-703	-1,136	1,765	1,447	1,866	2,499
(Inc)/Dec in FA	-187	-901	-1,433	-3,370	-1,726	-1,250	-4,050	-800
Free Cash Flow	184	-1,027	-2,136	-4,506	39	197	-2,184	1,699
(Pur)/Sale of Investments	-51	11	0	-2,300	605	0	0	0
Others	-888	-2,844	-7,711	5,388	69	451	941	1,201
CF from Investments	-1,127	-3,734	-9,144	-282	-1,052	-799	-3,109	401
Issue of Shares	331	2,715	9,682	0	0	10,000	0	0
Inc/(Dec) in Debt	-179	1,159	1,285	2,295	330	-3,200	-1,000	-300
Interest Paid	-70	-70	-216	-378	0	-427	-205	-132
Dividend Paid	0	0	0	0	-266	-288	-288	-288
Others	622	-303	-730	-187	1,326	-34	0	0
CF from Fin. Activity	705	3,500	10,022	1,730	1,389	6,050	-1,493	-721
Inc/Dec of Cash	-51	-360	175	312	2,102	6,697	-2,736	2,179
Opening Balance	780	729	369	544	856	2,958	9,655	6,919
Other cash & cash equivalent	0	0	0					
Closing Balance	729	369	544	856	2,958	9,655	6,919	9,098

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE). Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

.

Specific Disclosures

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email

Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.